Dexamthasone

DRUG2 trials

Sponsors

Amgen, VA Office of Research and Development

Conditions

Acute Lymphoblastic LeukemiaImmunotherapyNon-Small Cell Lung Cancer

Phase 1

Induction of Sensecence Using Dexamethasone to Re-sensitize NSCLC to Anti-PD1 Therapy

TerminatedNCT04037462

VA Office of Research and DevelopmentImmunotherapy, Non-Small Cell Lung Cancer

Start: 2021-07-07End: 2023-02-23Updated: 2024-06-14

Phase 3

Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)

CompletedNCT03476239

AmgenAcute Lymphoblastic Leukemia

Start: 2017-10-18End: 2021-04-08Updated: 2023-02-08

Related Papers

Efficacy and safety of blinatumomab in Chinese adults with Ph-negative relapsed/refractory B-cell precursor acute lymphoblastic leukemia: A multicenter open-label single-arm China registrational study.

2022-12-015 citations

Efficacy and safety of blinatumomab: Post hoc pooled analysis in Asian adults with relapsed/refractory B‐cell precursor acute lymphoblastic leukemia

Asia-Pacific Journal of Clinical Oncology2021-06-296 citations